Makoto Nishio - Concepedia

Author

Makoto Nishio

Japanese Foundation For Cancer Research ORCID

Also Known As

M Nishio, M. NISHIO, M. Nishio, MAKOTO NISHIO, Makoto NISHIO, Makoto Nishio, Masashi Nishio, Michiko Nishio, Mohamed Sehran, Nishio, M.

852

Publications

31.4K

Citations

H-Index

131

Concepts

All Affiliations

Japanese Foundation For Cancer Research The Cancer Institute Hospital Kindai University National Hospital Organization Kyushu Cancer Center National Cancer Center Hospital East

About

Makoto Nishio is an author at Japanese Foundation For Cancer Research specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	45	120	14.2K
2	Health Sciences	23	39	2.4K
3	Cell Biology	10	10	463
4	Engineering	6	6	170
5	Allergy	1	1	49

Makoto Nishio

262

Publications

28.7K

Citations

H-Index

Page 1

	Year	Citations
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, New England Journal of Medicine	2018	3.3K
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, The Lancet Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment	2019	2.1K
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer Jürgen Wolf, Takashi Seto, Ji‐Youn Han, New England Journal of Medicine	2020	957
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Martin Reck, Tony Mok, Makoto Nishio, The Lancet Respiratory Medicine Open-label Phase 3MedicinePathologyLiver MetastasesCancer Treatment	2019	919
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, The Lancet MedicineRandomised Phase 3PathologyAlectinib Versus CrizotinibBronchial Neoplasm	2017	895
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer Luc Friboulet, Nanxin Li, Ryohei Katayama, Cancer Discovery	2014	820
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, New England Journal of Medicine	2020	810
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) Stephen V. Liu, Martin Reck, Aaron S. Mansfield, Journal of Clinical Oncology	2021	763
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study Takashi Seto, Terufumi Kato, Makoto Nishio, The Lancet Oncology First-line TherapyOncologyPathologyEgfr MutationsCancer Treatment	2014	745
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, The Lancet Oncology Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment	2020	662

Page 1